Literature DB >> 32920697

Interplay between HMGA and TP53 in cell cycle control along tumor progression.

Nathalia Meireles Da Costa1, Antonio Palumbo2, Marco De Martino3, Alfredo Fusco3, Luis Felipe Ribeiro Pinto4, Luiz Eurico Nasciutti5.   

Abstract

The high mobility group A (HMGA) proteins are found to be aberrantly expressed in several tumors. Studies (in vitro and in vivo) have shown that HMGA protein overexpression has a causative role in carcinogenesis process. HMGA proteins regulate cell cycle progression through distinct mechanisms which strongly influence its normal dynamics along malignant transformation. Tumor protein p53 (TP53) is the most frequently altered gene in cancer. The loss of its activity is recognized as the fall of a barrier that enables neoplastic transformation. Among the different functions, TP53 signaling pathway is tightly involved in control of cell cycle, with cell cycle arrest being the main biological outcome observed upon p53 activation, which prevents accumulation of damaged DNA, as well as genomic instability. Therefore, the interaction and opposing effects of HMGA and p53 proteins on regulation of cell cycle in normal and tumor cells are discussed in this review. HMGA proteins and p53 may reciprocally regulate the expression and/or activity of each other, leading to the counteraction of their regulation mechanisms at different stages of the cell cycle. The existence of a functional crosstalk between these proteins in the control of cell cycle could open the possibility of targeting HMGA and p53 in combination with other therapeutic strategies, particularly those that target cell cycle regulation, to improve the management and prognosis of cancer patients.

Entities:  

Keywords:  Cancer; Cell cycle; Cell cycle-directed anti-cancer therapies; HMGA; TP53

Year:  2020        PMID: 32920697     DOI: 10.1007/s00018-020-03634-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  194 in total

1.  HMGA1 promoting gastric cancer oncogenic and glycolytic phenotypes by regulating c-myc expression.

Authors:  X P Cao; Y Cao; H Zhao; J Yin; P Hou
Journal:  Biochem Biophys Res Commun       Date:  2019-06-19       Impact factor: 3.575

2.  High-mobility-group A1 (HMGA1) proteins down-regulate the expression of the recombination activating gene 2 (RAG2).

Authors:  Sabrina Battista; Monica Fedele; Josefina Martinez Hoyos; Francesca Pentimalli; Giovanna Maria Pierantoni; Rosa Visone; Ivana De Martino; Carlo Maria Croce; Alfredo Fusco
Journal:  Biochem J       Date:  2005-07-01       Impact factor: 3.857

3.  CBX7 is a tumor suppressor in mice and humans.

Authors:  Floriana Forzati; Antonella Federico; Pierlorenzo Pallante; Adele Abbate; Francesco Esposito; Umberto Malapelle; Romina Sepe; Giuseppe Palma; Giancarlo Troncone; Marzia Scarfò; Claudio Arra; Monica Fedele; Alfredo Fusco
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

4.  HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity.

Authors:  Monica Fedele; Rosa Visone; Ivana De Martino; Giancarlo Troncone; Dario Palmieri; Sabrina Battista; Andrea Ciarmiello; Pierlorenzo Pallante; Claudio Arra; Rosa Marina Melillo; Kristian Helin; Carlo Maria Croce; Alfredo Fusco
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

5.  The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene.

Authors:  D Thanos; T Maniatis
Journal:  Cell       Date:  1992-11-27       Impact factor: 41.582

Review 6.  Roles of HMGA proteins in cancer.

Authors:  Alfredo Fusco; Monica Fedele
Journal:  Nat Rev Cancer       Date:  2007-12       Impact factor: 60.716

7.  Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2.

Authors:  Michela A Tessari; Monica Gostissa; Sandro Altamura; Riccardo Sgarra; Alessandra Rustighi; Clio Salvagno; Giuseppina Caretti; Carol Imbriano; Roberto Mantovani; Giannino Del Sal; Vincenzo Giancotti; Guidalberto Manfioletti
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

Review 8.  HMGA proteins as modulators of chromatin structure during transcriptional activation.

Authors:  Nihan Ozturk; Indrabahadur Singh; Aditi Mehta; Thomas Braun; Guillermo Barreto
Journal:  Front Cell Dev Biol       Date:  2014-03-06

9.  Binding of high mobility group A proteins to the mammalian genome occurs as a function of AT-content.

Authors:  Daniele F Colombo; Lukas Burger; Tuncay Baubec; Dirk Schübeler
Journal:  PLoS Genet       Date:  2017-12-21       Impact factor: 5.917

10.  Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth.

Authors:  Kang Yang; Wei Guo; Tingting Ren; Yi Huang; Yu Han; Hongliang Zhang; Jie Zhang
Journal:  J Exp Clin Cancer Res       Date:  2019-05-03
View more
  3 in total

1.  Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.

Authors:  Ziqi Huang; Baihui Li; Yan Guo; Lei Wu; Fan Kou; Lili Yang
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

2.  Network Pharmacology-Based Study on the Mechanism of Aloe Vera for Treating Cancer.

Authors:  Jing Xie; Jun Wu; Sihui Yang; Huaijun Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-01       Impact factor: 2.629

3.  Establishment and Validation of a Comprehensive Prognostic Model for Patients With HNSCC Metastasis.

Authors:  Yajun Shen; Lingyu Li; Yunping Lu; Min Zhang; Xin Huang; Xiaofei Tang
Journal:  Front Genet       Date:  2021-07-12       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.